Inhibition of cyclooxygenase-2 in experimental severe acute pancreatitis
DOI:
https://doi.org/10.1590/S1807-59322006000400005Keywords:
Acute pancreatitis, COX-2 inhibition, Parecoxib, InterleukinsAbstract
BACKGROUND: The standard treatment for acute pancreatitis (AP) is still based on supportive care. The search for a new drug that could change the natural history of the disease is a continuing challenge for many researchers. The aim of this study is to evaluate the effect of a cyclooxygenase-2 (COX-2) inhibitor on experimental AP in rats. METHODS: The animals were divided into 2 groups: Group 1 (n = 30)-animals with taurocholate-induced AP treated with parecoxib (40 mg/kg). Group 2 (n = 30)-animals with taurocholate-induced AP that received saline. The COX-2 inhibitor (parecoxib) was injected immediately after AP induction, through the penis dorsal vein. The parameters evaluated were histology, serum levels of amylase, IL-6 and IL-10, and mortality rate. RESULTS: The serum levels of IL-6 and IL-10 in the parecoxib-treated group were lower than the control group. The amylase serum levels and the mortality rate remained unchanged in the treated animals. Histologic morphology also was unaltered, except for fat necrosis, which was higher in parecoxib-treated rats. CONCLUSION: Inhibition of Cox-2 decreases the systemic release of inflammatory cytokines, but has a poor effect on the direct pancreas injury caused by taurocholate.Downloads
Download data is not yet available.
Downloads
Published
2006-08-01
Issue
Section
Original Research
How to Cite
Inhibition of cyclooxygenase-2 in experimental severe acute pancreatitis . (2006). Clinics, 61(4), 301-306. https://doi.org/10.1590/S1807-59322006000400005